دورية أكاديمية
أعرض في EDS

Role of Erythropoietin Receptor Signaling in Macrophages or Choroidal Endothelial Cells in Choroidal Neovascularization.

التفاصيل البيبلوغرافية
العنوان: Role of Erythropoietin Receptor Signaling in Macrophages or Choroidal Endothelial Cells in Choroidal Neovascularization.
المؤلفون: Ramshekar A; Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, 65 Mario Capecchi Dr, Salt Lake City, UT 84132, USA., Bretz CA; Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, 65 Mario Capecchi Dr, Salt Lake City, UT 84132, USA., Kunz E; Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, 65 Mario Capecchi Dr, Salt Lake City, UT 84132, USA., Cung T; Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, 65 Mario Capecchi Dr, Salt Lake City, UT 84132, USA., Richards BT; Sharon Eccles Steele Center for Translational Medicine, John A. Moran Eye Center, University of Utah, 65 Mario Capecchi Dr, Salt Lake City, UT 84132, USA., Stoddard GJ; Department of Internal Medicine, University of Utah, 30 N 1900 E, Salt Lake City, UT 84132, USA., Hageman GS; Sharon Eccles Steele Center for Translational Medicine, John A. Moran Eye Center, University of Utah, 65 Mario Capecchi Dr, Salt Lake City, UT 84132, USA., Chaqour B; Department of Ophthalmology, University of Pennsylvania, 422 Curie Boulevard, Philadelphia, PA 19104, USA., Hartnett ME; Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, 65 Mario Capecchi Dr, Salt Lake City, UT 84132, USA.
المصدر: Biomedicines [Biomedicines] 2022 Jul 09; Vol. 10 (7). Date of Electronic Publication: 2022 Jul 09.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101691304 Publication Model: Electronic Cited Medium: Print ISSN: 2227-9059 (Print) Linking ISSN: 22279059 NLM ISO Abbreviation: Biomedicines Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2013]-
مستخلص: Erythropoietin (EPO) has been proposed to reduce the progression of atrophic age-related macular degeneration (AMD) due to its potential role in neuroprotection. However, overactive EPO receptor (EPOR) signaling increased laser-induced choroidal neovascularization (CNV) and choroidal macrophage number in non-lasered mice, which raised the question of whether EPOR signaling increased CNV through the recruitment of macrophages to the choroid that released pro-angiogenic factors or through direct angiogenic effects on endothelial cells. In this study, we addressed the hypothesis that EPOR signaling increased CNV by direct effects on macrophages or endothelial cells. We used tamoxifen-inducible macrophage-specific or endothelial cell-specific EPOR knockout mice in the laser-induced CNV model, and cultured choroidal endothelial cells isolated from adult human donors. We found that macrophage-specific knockout of EPOR influenced laser-induced CNV in females only, whereas endothelial-specific knockout of EPOR reduced laser-induced CNV in male mice only. In cultured human choroidal endothelial cells, knockdown of EPOR reduced EPO-induced signal transducer and activator of transcription 3 (STAT3) activation. Taken together, our findings suggest that EPOR signaling in macrophages or choroidal endothelial cells regulates the development of CNV in a sex-dependent manner. Further studies regarding the role of EPO-induced signaling are required to assess EPO safety and to select or develop appropriate therapeutic approaches.
References: BMC Res Notes. 2009 Nov 25;2:234. (PMID: 19930719)
Invest Ophthalmol Vis Sci. 2013 Jul 24;54(7):4974-81. (PMID: 23800770)
N Engl J Med. 2002 Dec 12;347(24):1968-70. (PMID: 12477950)
Blood. 2021 Nov 18;138(20):1986-1997. (PMID: 34098576)
Ophthalmologica. 2005 Jul-Aug;219(4):214-21. (PMID: 16088240)
Ophthalmology. 2020 Sep;127(9):1191-1200. (PMID: 32359843)
Ophthalmology. 2020 Jun;127(6):784-792. (PMID: 31899035)
Sci Rep. 2018 Feb 1;8(1):2161. (PMID: 29391474)
Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):986-91. (PMID: 11158582)
Ophthalmology. 2018 Mar;125(3):369-390. (PMID: 29110945)
Nat Rev Dis Primers. 2021 May 6;7(1):31. (PMID: 33958600)
Eye (Lond). 2016 Oct;30(10):1293-1309. (PMID: 27285322)
Nat Protoc. 2013 Nov;8(11):2197-211. (PMID: 24136346)
Kidney Int. 2006 Jul;70(2):246-50. (PMID: 16738535)
Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9126-31. (PMID: 8799165)
Sci Rep. 2020 Dec 3;10(1):21093. (PMID: 33273512)
Am J Pathol. 2007 Jun;170(6):2149-58. (PMID: 17525280)
Ophthalmology. 2016 Aug;123(8):1751-1761. (PMID: 27156698)
Int J Mol Sci. 2017 Jul 13;18(7):. (PMID: 28703764)
Cell. 1995 Oct 6;83(1):59-67. (PMID: 7553874)
Blood. 2010 May 27;115(21):4264-72. (PMID: 20124513)
Exp Eye Res. 2020 Nov;200:108204. (PMID: 32910939)
Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):23. (PMID: 32785675)
Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5464-72. (PMID: 18055794)
Trends Endocrinol Metab. 1999 Dec;10(1):18-23. (PMID: 10322390)
JAMA Ophthalmol. 2020 May 1;138(5):510-518. (PMID: 32191267)
Ophthalmology. 2019 Feb;126(2):252-260. (PMID: 30189282)
Nat Methods. 2012 Jun 28;9(7):676-82. (PMID: 22743772)
Cardiovasc Res. 2014 Oct 1;104(1):171-82. (PMID: 25082847)
Exp Eye Res. 2021 Aug;209:108641. (PMID: 34058230)
Am J Pathol. 2020 Mar;190(3):630-641. (PMID: 32093902)
Hum Mol Genet. 2022 Jul 21;31(14):2406-2423. (PMID: 35181781)
Am J Pathol. 2014 Apr;184(4):1230-1239. (PMID: 24630601)
Haematologica. 2010 Nov;95(11):1823-31. (PMID: 20595096)
Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):24100-24107. (PMID: 31712411)
Front Immunol. 2014 Oct 22;5:523. (PMID: 25374571)
FASEB J. 2021 Jul;35(7):e21642. (PMID: 34166557)
Am J Pathol. 2003 Sep;163(3):993-1000. (PMID: 12937140)
Med Hypotheses. 2009 Apr;72(4):448-50. (PMID: 19128888)
J Am Soc Nephrol. 2022 Apr;33(4):850-866. (PMID: 35361724)
Nat Med. 2002 Jul;8(7):718-24. (PMID: 12068288)
Genome Med. 2012 Feb 24;4(2):16. (PMID: 22364233)
Lancet Glob Health. 2014 Feb;2(2):e106-16. (PMID: 25104651)
Antioxidants (Basel). 2021 May 25;10(6):. (PMID: 34070383)
Cell Immunol. 2016 Aug-Sep;306-307:17-24. (PMID: 27262376)
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3974-8. (PMID: 8171022)
معلومات مُعتمدة: F30 EY032311 United States EY NEI NIH HHS; R01EY017011 United States EY NEI NIH HHS; P30 EY014800 United States EY NEI NIH HHS; R01 EY017011 United States EY NEI NIH HHS; P30EY014800 United States EY NEI NIH HHS; R01 EY015130 United States EY NEI NIH HHS; R01 EY024998 United States EY NEI NIH HHS; F30EY032311 United States EY NEI NIH HHS; R03 EY014552 United States EY NEI NIH HHS; R01EY015130 United States EY NEI NIH HHS; T32 EY024234 United States EY NEI NIH HHS; R01EY024998 United States EY NEI NIH HHS
فهرسة مساهمة: Keywords: AMD; CECs; CNV; EPO; EPOR; macrophages
تواريخ الأحداث: Date Created: 20220727 Latest Revision: 20240515
رمز التحديث: 20240515
مُعرف محوري في PubMed: PMC9312702
DOI: 10.3390/biomedicines10071655
PMID: 35884958
قاعدة البيانات: MEDLINE
الوصف
تدمد:2227-9059
DOI:10.3390/biomedicines10071655